The finding that all cases were among pre-menopausal breast cancer cases but not among patients with post-menopausal breast cancer or ovarian cancer is consistent with previous studies showing prevalence of germline ATM mutations detected by sequencing in patients with familial early-onset breast cancer [34] or by p53-MCL in sporadic breast cancer [14]. The gene discussed is TP53; the disease is ovarian carcinoma.